Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance

BACKGROUND: Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and afatinib in combination for patients with resistant EGFR-mutant lung cancer. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Creelan, Ben C., Gray, Jhanelle E., Tanvetyanon, Tawee, Chiappori, Alberto A., Yoshida, Takeshi, Schell, Michael J., Antonia, Scott J., Haura, Eric B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474279/
https://www.ncbi.nlm.nih.gov/pubmed/30880334
http://dx.doi.org/10.1038/s41416-019-0428-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474279/
https://www.ncbi.nlm.nih.gov/pubmed/30880334
http://dx.doi.org/10.1038/s41416-019-0428-3

Ejemplares similares